In a case-control study, Kegeles et al measure γ-aminobutyric acid and glutamate-glutamine levels in vivo in 2 prefrontal brain regions in unmedicated and medicated patients with schizophrenia and healthy controls.
The relationship and shared genetic origin between premorbid IQ and psychotic disorders in a longitudinal population-based cohort is examined by Fowler et al.
Werbeloff et al investigate the suggestion that attenuated psychotic symptoms reported by people who do not have psychotic disorders signal risk for later severe mental illness. They use follow-up assessments of hospitalization for clinical diagnoses of nonaffective psychotic and other psychiatric disorders.
Tiihonen et al investigate if the use of benzodiazepines, antidepressants, or multiple concomitant antipsychotics is associated with increased mortality among patients with schizophrenia and conclude that benzodiazepine use may contribute to mortality among this patient population worldwide.
Joffe et al evaluate whether previous affective illness is associated with low health-related quality of life during midlife in the absence of current illness episodes.
Barnes and coauthors examined depressive symptoms assessed in midlife and late life to assess the timing and nature of depression as etiologic risk factors for dementia.
Boyle and coauthors used data from a longitudinal epidemiologic, clinicopathologic study of aging that included detailed annual clinical evaluations and brain autopsy to determine the risk of Alzheimer disease in persons with a strong sense of purpose in life.
Katon et al evaluate the cost-effectiveness of a multicondition collaborative treatment program compared with usual primary care in outpatients with depression and poorly controlled diabetes mellitus or coronary heart disease.
Geller and coauthors investigate which medication to administer first to antimanic medication–naive subjects. The Treatment of Early Age Mania study recruited 6- to 15-year-old children and adolescents with DSM-IV bipolar I disorder (manic or mixed phase) at 5 US sites from 2003 to 2008 into a controlled, randomized, no-patient-choice, 8-week protocol.
In a case-control study, Grosshans and coauthors assess changes in regional brain activations in response to food-related cues in association with body mass index and the plasma concentration of the appetite regulating peptide leptin.